AGE-Breaker ALT-711 Plus Insulin Could Restore Erectile Function in Streptozocin-Induced Type 1 Diabetic Rats

Journal of Sexual Medicine

Volumn 11, Issue 6, 2014, Pages 1452-1462

  Wang, Lin ^a   Tian, Wenjie ^b   Uwais, Zaid ^c   Li, Guangyong ^d   Li, Huixi ^a   Guan, Ruili ^a   Gao, Zhezhu ^a   Xin, Zhongcheng ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

Diabetes Mellitus; Erectile Dysfunction; Metabolic Memory; Oxidative Stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALAGEBRIUM; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; NITRIC OXIDE SYNTHASE; STREPTOZOCIN; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CAVERNOUS NERVE; CONTROLLED STUDY; DORSAL NERVE; DOWN REGULATION; DRUG EFFICACY; ELECTROSTIMULATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ERECTILE DYSFUNCTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HISTOLOGY; INTRACAVERNOUS PRESSURE; LIPID PEROXIDATION; MALE; MONOTHERAPY; NERVE; NONHUMAN; OXIDATIVE STRESS; PRESSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TREATMENT DURATION;

DIABETES MELLITUS; ERECTILE DYSFUNCTION; METABOLIC MEMORY; OXIDATIVE STRESS;

ANIMALS; APOPTOSIS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; ERECTILE DYSFUNCTION; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MALONDIALDEHYDE; NITRIC OXIDE SYNTHASE TYPE I; OXIDATIVE STRESS; PENILE ERECTION; PENIS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; THIAZOLES;

EID: 84902118195     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12533     Document Type: Article

References (26)

1. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84:50-56.
2. Ponholzer A, Temml C, Mock K, Marszalek M, Obermayr R, Madersbacher S. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol 2005;47:80-85, discussion 85-6.
3. Thorve VS, Kshirsagar AD, Vyawahare NS, Joshi VS, Ingale KG, Mohite RJ. Diabetes-induced erectile dysfunction: Epidemiology, pathophysiology and management. J Diabetes Complications 2011;25:129-136.
4. Cheitlin MD. Erectile dysfunction: The earliest sign of generalized vascular disease? J Am Coll Cardiol 2004;43:185-186.
5. Dogra G, Rich L, Stanton K, Watts GF. Endothelium-dependent and independent vasodilation studies at normoglycaemia in type I diabetes mellitus with and without microalbuminuria. Diabetologia 2001;44:593-601.
6. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 2003;26:1589-1596.
7. Kowluru RA. Effect of reinstitution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes 2003;52:818-823.
8. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997;272:17810-17814.
9. Vasan S, Foiles P, Founds H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys 2003;419:89-96.
10. Wolffenbuttel BH, Boulanger CM, Crijns FR, Huijberts MS, Poitevin P, Swennen GN, Vasan S, Egan JJ, Ulrich P, Cerami A, Levy BI. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci U S A 1998;95:4630-4634.
11. Zieman SJ, Melenovsky V, Clattenburg L, Corretti MC, Capriotti A, Gerstenblith G, Kass DA. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens 2007;25:577-583.
12. Usta MF, Kendirci M, Gur S, Foxwell NA, Bivalacqua TJ, Cellek S, Hellstrom WJ. The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: preventive versus curative treatment. J Sex Med 2006;3:242-250, discussion 250-242.
13. Choi WS, Park K, Paick JS, Kim SW. Time-dependent changes of erectile function in diabetic rats: Role of systemic endothelial dysfunction. World J Mens Health 2012;30:114-122.
14. Cho SY, Chai JS, Lee SH, Park K, Paick JS, Kim SW. Investigation of the effects of the level of glycemic control on erectile function and pathophysiological mechanisms in diabetic rats. J Sex Med 2012;9:1550-1558.
15. Yuan YV, Kitts DD, Godin DV. Heart and red blood cell antioxidant status and plasma lipid levels in the spontaneously hypertensive and normotensive Wistar Kyoto rat. Can J Physiol Pharmacol 1996;74:290-297.
16. Kim SY, Kim JW, Ko YS, Koo JE, Chung HY, Lee-Kim YC. Changes in lipid peroxidation and antioxidant trace elements in serum of women with cervical intraepithelial neoplasia and invasive cancer. Nutr Cancer 2003;47:126-130.
17. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.
18. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139.
19. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653.
20. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000;275:25781-25790.
21. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-248.
22. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-1407.
23. Freidja ML, Tarhouni K, Toutain B, Fassot C, Loufrani L, Henrion D. The AGE-breaker ALT-711 restores high blood flow-dependent remodeling in mesenteric resistance arteries in a rat model of type 2 diabetes. Diabetes 2012;61:1562-1572.
24. Gurbuz N, Sagdic G, Sanli A, Ciftcioglu A, Bassorgun I, Baykal A, Usta MF. Therapeutic effect of combination of alagebrium (ALT-711) and sildenafil on erectile function in diabetic rats. Int J Impot Res 2012;24:114-121.
25. Silva FH, Monica FZ, Bau FR, Brugnerotto AF, Priviero FB, Toque HA, Antunes E. Superoxide anion production by NADPH oxidase plays a major role in erectile dysfunction in middle-aged rats: prevention by antioxidant therapy. J Sex Med 2013;10:960-971.
26. Zhou F, Xin H, Liu T, Li GY, Gao ZZ, Liu J, Li WR, Cui WS, Bai GY, Park NC, Xin ZC. Effects of icariside II on improving erectile function in rats with streptozotocin-induced diabetes. J Androl 2012;33:832-844.